Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tissue Archiving May Preclude Prospective Data In Deciding Assay Utility

This article was originally published in The Gray Sheet

Executive Summary

Drug companies anticipating use of molecular assays to complement therapies under development could be encouraged to rely on tissue-banked specimen analyses in lieu of prospective, randomized trials demonstrating clinical utility

You may also be interested in...



NCI-FDA Panel Will Publish Draft Guidelines On Cancer Assay Development

FDA Division of Clinical Laboratory Devices Director Steve Gutman is serving on a National Cancer Institute panel that will issue draft guidelines on cancer marker and assay development and publication of studies by early 2002

NCI-FDA Panel Will Publish Draft Guidelines On Cancer Assay Development

FDA Division of Clinical Laboratory Devices Director Steve Gutman is serving on a National Cancer Institute panel that will issue draft guidelines on cancer marker and assay development and publication of studies by early 2002

Abbott/Vysis’ PathVysion HER-2 Assay Endorsed By Herceptin Panel Review

Genentech's Herceptin package insert to include use of Vysis' PathVysion fluorescence in situ hybridization (FISH) test should address potential discrepancies in assay results compared with immunohistochemistry (IHC) tests, FDA's Oncologic Drugs Advisory Committee concluded

Related Content

UsernamePublicRestriction

Register

MT015830

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel